Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  QS21
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 37 for your search:
Start Over
Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
Vaccine Therapy in Treating Patients With Primary Stage II Melanoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: CDR0000067645, EORTC-18961, BMS-CA152-003, NCT00005052
Phase I/II Pilot Study of Vaccination with Tyrosinase Peptides or Proteins or Tyrosinase-KLH Conjugate plus QS-21 in High-Risk Stage III/IV Melanoma (Summary Last Modified 06/95)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-94029, NCI-V94-0467
Phase I/II Study of Vaccination with Tumor-Specific CML Breakpoint Peptides plus QS21 for Chronic Myelogenous Leukemia in Partial or Complete Remission (Summary Last Modified 01/1998)
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: MSKCC-95029A3, NCI-H95-0683
Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)
Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor:
Protocol IDs: MSKCC-94009A1, NCI-V94-0458
Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: MSKCC-94041, NCI-H94-0471
Phase II Study of Vaccination with Tn(c)-KLH Conjugate Plus the Immunological Adjuvant QS21 in Patients with Prostate Cancer (Summary Last Modified 05/1999)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98002, NCI-G98-1440
Phase II Pilot Study of a Multivalent Conjugate Vaccine With Adjuvant QS21 in Patients With Biochemically Relapsed Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-00064, NCI-G01-1940, NCT00016120
Phase II Pilot Study of Vaccination with Sialyl Tn Antigen Covalently Attached to KLH plus QS21 in High-Risk Resected Colorectal Cancer (Summary Last Modified 07/95)
Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92100, NCI-V92-0144
Phase I Trial of Vaccination with a Tyrosinase Peptide and Immunologic Adjuvant QS21 in Stage IV Melanoma (Summary Last Modified 02/1999)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: MSKCC-95052, NCI-H95-0769
Phase IB Study of Vaccination with a Recombinant Mutant ras Protein with the Immunologic Adjuvant QS21 in Patients with Adenocarcinomas Expressing an Activated ras Oncoprotein (Summary Last Modified 03/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-97-C-0018, CRB-9411, NCI-NMOB-9608, NCI-T95-0048N, T95-0048
Phase I Pilot Study of Vaccination with Recombinant Mutant ras Peptide with the Immunologic Adjuvant QS21 in Advanced Pancreatic Adenocarcinoma (Summary Last Modified 04/2000)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: RPCI-DS-94-23, FCCC-98025, NCI-V96-1035
Phase I Study of Vaccination with Globo H-KLH Conjugate with the Immunologic Adjuvant QS21 for Recurrent Prostate Cancer (Summary Last Modified 09/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-96055A1, NCI-V97-1119
Phase I Study of GM2-KLH Vaccine Plus the Immunological Adjuvant QS21 for Prostate Cancer (Summary Last Modified 06/98)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-97097, NCI-G97-1340
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 79
Sponsor: NCI, Other
Protocol IDs: 6346, NCI-H98-0010, UVACC-HIC-6346, UVA-HIC-6346, NCT00003224
Start Over